GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$242.01
+3.85%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$237.18
From 52W high−0.20%
Volume388817.00
Market cap$14.33B
P/E (TTM)—
P/S (TTM)20.8x
Div yield—
Key dataNov 4, 2026
Open
$237.18
From 52W high
−0.20%
Volume
388817.00
Market cap
$14.33B
ValuationView details →
P/E (Fwd)
181.8x
EV/EBITDA
−113.6x
P/E (TTM)
—
RSI (14)
82.0
MomentumView details →
1D Return
+3.85%
YTD Return
+110.60%
SummaryUpdated Sep 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
GLAUKOS Corp shares rose 18% in premarket trading after the company reported an unexpected third-quarter profit.6d agoGLAUKOS Corp reported quarterly earnings of $0.47 per share, compared with a loss of $0.16 per share a year earlier, surpassing the Zacks consensus estimate of a loss of $0.12 per share.7d agoGlaukos Corp. reported third-quarter 2026 revenue of $211.0 million, net income of $2.0 million and diluted earnings per share of $0.03.7d ago